TRILUMINATE Pivotal - 2-year update EuroPCR 25, presented by G. Singh
The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement
LEARN MORE:
Related Resources
Poster: Primary MR in the Very Elderly
Prognosis of TR after MitraClip for MR
bRIGHT 2-year real-world outcomes
bRIGHT study
Data Summary PFO closure in patients > 60 Years
ACC 2023: COAPT™ trial
EuroPCR 2022: TAVI 1yr outcomes
2-year outcomes from the TRILUMINATE Pivotal trial
EXPAND Study: Data overview
ESC 2021: HF & VHD Guidelines
TRENDING TOPICS
TEER G5 Brochure 2025
Poster: Primary MR in the Very Elderly
Prognosis of TR after MitraClip for MR
